Navigation Links
If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
Date:2/11/2009

Genentech/Roche/Chugai's Drug in Combination With Herceptin and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that if Genentech/Roche/Chugai's Herceptin is approved in combination with emerging therapies, it will be in a position to retain patient share from GlaxoSmithKline's Tykerb/Tyverb for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This is particularly true in the second- and subsequent HER2-positive treatment lines which are currently its most vulnerable market segments.

The new report entitled HER2-Positive Breast Cancer: Oncologists Are Eager for Improvements in Overall Survival Compared with Trastuzumab in the Metastatic Setting also finds that Genentech/Roche/Chugai's pertuzumab in combination with Herceptin and Sanofi Aventis' Taxotere will become Decision Resources' proprietary clinical gold standard regimen for HER2-positive breast cancer by 2017. This will occur following its approval for the indication in combination with Herceptin and Taxotere in 2013.

"Based on surveys and interviews we conducted with U.S. and European oncologists, as well as comparative drug analysis using our proprietary drug comparator model, we concluded that pertuzumab will have competitive advantages in efficacy when used in combination with Herceptin and Taxotere versus using Herceptin and Taxotere alone," stated Niamh Murphy, Ph.D., analyst at Decision Resources.

About the Report

HER2-Positive Breast Cancer: Oncologists are Eager for Improvements in Overall Survival Compared with Trastuzumab in the Metastatic Setting is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
2. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
3. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
4. Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement
5. A Newly Approved CMS Medicare Package Expands Reimbursement Coverage for Telehealth Originating Sites Beginning January 1, 2009
6. CSL Behring Receives FDA Approval of RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
7. Alliance for Pediatric Quality Supports New ANSI-Approved Standard for Child Health Passed by HL7
8. New Roche Dual Target HIV-1 Test Approved for Use in European Union
9. The First Treatment Specifically Approved for Huntingtons Disease Patients is Now Available in the United States
10. Bayer Marketing Two Unapproved Aspirin Products: FDA
11. Upscale New York City Skin Care Center Juva Offering FDA Approved Fraxel re:fine System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
Breaking Medicine Technology: